By Colin Kellaher

 

Amgen Inc., Cytokinetics Inc. and Laboratoires Servier SA on Thursday said a pivotal phase 3 study of omecamtiv mecarbil in patients with heart failure met its primary composite endpoint but missed its secondary endpoint.

The companies said treatment with omecamtiv mecarbil showed a statistically significant effect to reduce cardiovascular death or heart failure events compared to placebo in patients with heart failure with reduced ejection fraction.

However, the companies said no reduction in the secondary endpoint of cardiovascular death was observed, adding that adverse events, including major ischemic cardiac events, were balanced between treatment arms. Further analyses of the study data are underway, the companies said.

Amgen, a Thousand Oaks, Calif., biotechnology company, in 2006 formed a collaboration with South San Francisco, Calif., biopharmaceutical company Cytokinetics to discover, develop and commercialize potential treatments for heart failure. The companies are developing omecamtiv mecarbil with funding and strategic support from French drug company Servier.

Shares of Cytokinetics, which closed Wednesday at $27.66, were down more than 37% in premarket trading Thursday. Amgen shares slipped 3.4% premarket.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 08, 2020 09:09 ET (13:09 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Amgen Charts.